KYMR
Kymera Therapeutics Inc
109.90$
+2.3%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +4.2% | +50.8% | -4.9% | +25.3% | -5.5% | -6.1% | +23.2% | -2.6% | +58.1% | -4.2% | -1.4% | |
| – | +7.9% | +32.6% | -2.2% | +8.2% | -10.3% | -1.8% | +45.4% | -27.5% | +64.9% | -22.2% | +8.8% | |
| – | +35.7% | -15.0% | -27.7% | +63.8% | +8.6% | -25.2% | +273.3% | -66.4% | +216.1% | -59.6% | -13.6% | |
| – | +4.8% | +38.9% | -2.0% | +7.8% | -11.1% | -5.2% | +43.7% | -24.0% | +67.7% | -23.3% | +6.2% | |
| – | +396.6% | -89.2% | -16.1% | -22.7% | -28.1% | +2,011.9% | +100.0% | – | – | – | – | |
| – | – | +0.0% | – | – | – | – | – | – | – | – | – | |
| – | +15.3% | -13.1% | -10.2% | +0.6% | +0.4% | -7.3% | +20.8% | -2.4% | +4.7% | -20.7% | +8.1% | |
| – | +35.7% | -34.5% | +10.7% | +7.1% | +1.9% | -13.0% | +48.4% | -18.2% | +16.3% | -24.7% | +19.7% | |
| – | +76.5% | +55.9% | +25.5% | +3.5% | +2.0% | +1.0% | +3.2% | +0.6% | +0.1% | -0.2% | +26.4% | |
| – | +42.1% | -3.7% | -4.4% | -0.2% | -7.8% | +71.4% | -43.7% | -4.8% | -27.1% | +219.8% | -30.5% | |
| – | -0.1% | +80.1% | -3.7% | +30.4% | -6.4% | -5.9% | +23.6% | -2.6% | +66.9% | -2.5% | -2.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.2% | +20.9% | +3.2% | +4.2% | +5.1% | +0.2% | +0.4% | +8.5% | -3.3% | +15.6% | +0.7% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.